Sunitinib - Pfizer

Alternative Names: PHA-290940; PHA-290940AD; PNU-290940; PNU-290940AD; SU-011248; SU-11248; SU-11428; Sunitinib malate; Sutent

Latest Information Update: 05 Nov 2023

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Pfizer
Developer Australasian Sarcoma Study Group; Cancer Research UK; Case Comprehensive Cancer Center; Clatterbridge Cancer Centre NHS Foundation Trust; Dana-Farber Cancer Institute; Hoosier Cancer Research Network; Korean Urological Oncology Society; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); Ohio State University; Pfizer; University of Michigan Comprehensive Cancer Center; University of Texas M. D. Anderson Cancer Center; US Oncology Research
Class Amides; Antineoplastics; Ethylamines; Eye disorder therapies; Fluorobenzenes; Indoles; Pyrroles; Small molecules
Mechanism of Action Angiogenesis inhibitors; Colony-stimulating factor receptor antagonists; Fms-like tyrosine kinase 3 inhibitors; Platelet-derived growth factor alpha receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Proto-oncogene protein c-kit inhibitors; Proto-oncogene protein c-ret inhibitors; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists; Vascular endothelial growth factor receptor-3 antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Pancreatic cancer; Gastrointestinal stromal tumours; Renal cell carcinoma
New Molecular Entity Yes

Marketed Gastrointestinal stromal tumours; Pancreatic cancer; Renal cell carcinoma
Phase II Alveolar soft part sarcoma; Bladder cancer; Neuroendocrine tumours; Oesophageal cancer; Phaeochromocytoma; Prostate cancer; Thyroid cancer; Uveal melanoma
Phase I/II Soft tissue sarcoma
No development reported Germ cell cancer; Liver cancer
Discontinued Acral lentiginous melanoma; Breast cancer; Colorectal cancer; Gastric cancer; Non-small cell lung cancer; Urogenital cancer

01 Nov 2022 Efficacy data in Prostrate cancer presented at 47th European Society for Medical Oncology Congress (ESMO-2022)
06 Jun 2022 Phase-II clinical trials in Alveolar soft part sarcoma (Inoperable/Unresectable, Metastatic disease, Late-stage disease, Monotherapy, Second-line therapy or greater) in USA (PO) in July 2011 (NCT01391962)
23 May 2022 Pfizer in collaboration with Assistance Publique - Hôpitaux de Paris terminates a phase III CARMENA trial in Renal cell carcinoma (Metastatic-disease, Late-stage disease, Monotherapy) in France (PO) due to slow recruitment, and the results from interim analysis were sufficient to meet the objectives of the trial (NCT00930033)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com